Literature DB >> 29858937

Hepatic neuroendocrine tumors: gadoxetic acid-enhanced magnetic resonance imaging findings with an emphasis on differentiation between primary and secondary tumors.

Dong Ik Cha1, Tae Wook Kang2, Kyoung Mi Jang1, Young Kon Kim1, Seong Hyun Kim1, Sang Yun Ha3, Insuk Sohn4.   

Abstract

PURPOSE: To describe the findings of magnetic resonance (MR) imaging of hepatic neuroendocrine tumors (hNET) and to identify the features that differentiate secondary from primary tumors.
METHODS: This retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. Between August 2008 and December 2014, 50 patients with pathologically proven hNETs who underwent gadoxetic acid-enhanced MR imaging with diffusion-weighted images were included. The patients were divided into two groups according to whether they had primary (n = 17) or secondary (n = 33) hNETs. Qualitative values based on a consensus between two observers [morphologic findings, signal intensity, and enhancement pattern (poor or indeterminate; hepatocellular carcinoma-like or cholangiocarcinoma-like)], and quantitative values (apparent diffusion coefficient) were evaluated as predictors of secondary hNETs using multivariable logistic regression and receiver operating characteristic (ROC) analysis.
RESULTS: In multivariate analysis, the presence of multiple lesions (p = 0.011), a tumor size less than 6.3 cm (p = 0.001), and a hepatocellular carcinoma-like enhancement pattern (p = 0.031) were significant independent factors for differentiating secondary from primary hNETs, and achieved a sensitivity of 91%, a specificity of 82%, and an accuracy of 88%, with a value of the area under the ROC curve of 0.931.
CONCLUSION: Using these specific MR imaging criteria, secondary hNETs could be differentiated from primary hNETs with a high degree of accuracy in patients with histopathologically proven hNETs.

Entities:  

Keywords:  Diagnosis; Imaging criteria; Liver; Magnetic resonance imaging; Neuroendocrine tumor

Mesh:

Substances:

Year:  2018        PMID: 29858937     DOI: 10.1007/s00261-018-1653-6

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  4 in total

1.  Complete Response After Pre-Operative Transcatheter Arterial Chemoembolization for Unresectable Primary Hepatic Neuroendocrine Tumour: A Case Report and Literature Review.

Authors:  Xinyuan Zhang; Huiru Yang; Yujing Xin; Yi Yang; Haizhen Lu; Xiang Zhou
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

Review 2.  Treatment of primary hepatic neuroendocrine tumors with associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): A case report and literature review.

Authors:  Chao Qu; Lin-Lin Qu; Cheng-Zhan Zhu; Zu-Sen Wang; Jingyu Cao
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

3.  Primary hepatic neuroendocrine tumors: A case report.

Authors:  Hai-Xia Hu; Tong Yu
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

4.  Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.

Authors:  Shintaro Ichikawa; Utaroh Motosugi; Hiroyuki Morisaka; Kazuto Kozaka; Satoshi Goshima; Tomoaki Ichikawa
Journal:  Magn Reson Med Sci       Date:  2020-02-27       Impact factor: 2.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.